Proactive Investors - Run By Investors For Investors

Regeneus enters strategic collaboration

Regeneus (ASX:RGS) has been granted a trading halt by the ASX this morning, with its shares placed in pre-open.
Regeneus enters strategic collaboration
Regeneus has been granted a trading halt.

Regeneus requested the halt pending details on the signing of transaction documents and information relating to the entry into a strategic collaboration and licensing agreement for Progenza stem cell technology in Japan.

The halt will remain in place until the opening of trade on Friday 30th December 2016, or earlier if an announcement is made to the market.

View full RGS profile View Profile

Regeneus Ltd Timeline

Related Articles

human kidneys
May 06 2019
The Danish company is seeking FDA approval of the test for use in both adults and children
Empty lab
September 19 2018
Management has made some tough decisions, cutting the cost base, since a disappointing first-half performance and expects the benefits to really kick in next year
scientists in a lab
January 31 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use